Kilter Group LLC Buys New Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Kilter Group LLC acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 43,539 shares of the company's stock, valued at approximately $1,053,000. Hims & Hers Health accounts for approximately 0.7% of Kilter Group LLC's investment portfolio, making the stock its 17th biggest position.

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in Hims & Hers Health by 11.1% in the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock valued at $489,817,000 after purchasing an additional 2,020,722 shares during the last quarter. Farallon Capital Management LLC raised its stake in shares of Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after buying an additional 8,364,000 shares during the period. Renaissance Technologies LLC lifted its position in shares of Hims & Hers Health by 29.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock valued at $168,079,000 after buying an additional 1,562,302 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its stake in shares of Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after acquiring an additional 4,145,305 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Hims & Hers Health by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock worth $104,724,000 after acquiring an additional 40,447 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Price Performance

NYSE HIMS traded up $0.08 during trading on Wednesday, reaching $53.44. The company's stock had a trading volume of 19,561,447 shares, compared to its average volume of 19,636,135. The stock has a market capitalization of $11.96 billion, a PE ratio of 121.46 and a beta of 1.84. The firm has a fifty day moving average of $38.78 and a 200 day moving average of $35.51. Hims & Hers Health, Inc. has a one year low of $13.47 and a one year high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $586.01 million for the quarter, compared to the consensus estimate of $535.21 million. During the same period last year, the firm posted $0.05 earnings per share. Hims & Hers Health's quarterly revenue was up 110.7% on a year-over-year basis. Research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Leerink Partners raised their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a report on Tuesday, February 25th. Needham & Company LLC reissued a "buy" rating and set a $61.00 target price on shares of Hims & Hers Health in a report on Tuesday, May 6th. Truist Financial dropped their target price on Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a research report on Thursday, April 10th. Finally, Morgan Stanley reduced their price target on Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating for the company in a research report on Tuesday, April 29th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $37.67.

Insider Activity

In related news, CEO Andrew Dudum sold 128,127 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $33.98, for a total value of $4,353,755.46. Following the completion of the sale, the chief executive officer now owns 173,655 shares in the company, valued at $5,900,796.90. The trade was a 42.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Irene Becklund sold 2,203 shares of the stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $28.78, for a total transaction of $63,402.34. Following the transaction, the insider now owns 8,007 shares in the company, valued at $230,441.46. The trade was a 21.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 606,704 shares of company stock worth $24,621,075. 13.71% of the stock is currently owned by corporate insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.